-
Mashup Score: 1HBI-8000 Plus Nivolumab Is Safe, Active in Melanoma - 4 hour(s) ago
The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no prior anti–PD-1/PD-L1 treatment.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Insights on Tucatinib Regimens in HER2+ Breast Cancer Treatment - 16 hour(s) ago
Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer treatment
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In this video, Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer treatment #bcsm | @DFCI_BreastOnc https://t.co/gINoCBpTfN
-
-
Mashup Score: 7Capivasertib Improves PFS in PTEN-Deficient mHSPC - 19 hour(s) ago
Data from the phase 3 CAPItello-281 trial showed that capivasertib plus abiraterone and androgen deprivation therapy significantly improved radiographic progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In the phase 3 CAPItello-281 trial, capivasertib + abiraterone and androgen deprivation therapy significantly improved radiographic progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer. #pcsm https://t.co/6THj1yuxkZ
-
-
Mashup Score: 3Exploring Immunotherapy and Radiation Therapy in Cervical Cancer - 22 hour(s) ago
Domenica Lorusso, MD, PhD, discusses the rationale behind the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Domenica Lorusso, MD, PhD, discusses the rationale behind the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. #gyncsm https://t.co/0MeUWspHo2
-
-
Mashup Score: 0
The FDA accepted darolutamide’s application for metastatic hormone-sensitive prostate cancer, imatinib is now in liquid form, and ribociclib, combined with an NSAI, showed significant benefit in high-risk, node-negative early-stage breast cancer. Brexu-cel demonstrated CNS remission in relapsed/refractory B-ALL, and a new vaccine shows promise in breast cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The FDA accepted darolutamide for metastatic hormone-sensitive prostate cancer, imatinib is now available in liquid form, and ribociclib + NSAI showed benefit in high-risk early-stage breast cancer. https://t.co/pihWtuXvWf
-
-
Mashup Score: 3November 2024 FDA Updates: Key Developments in Oncology - 1 day(s) ago
Here is a look back on all the FDA happenings from the month of November 2024.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
November 2024 was a significant month for the FDA, with numerous approvals, designations, and clinical trial advancements in the oncology space. Here is a look back on all the FDA happenings from the month: https://t.co/v1VmpNyH8K
-
-
Mashup Score: 2
Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with leptomeningeal metastasis.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Barbara O’Brien, MD, discussed the findings and implications from the phase 2 TBCRC049 study. #bcsm | @barbaraobrienmd @MDAndersonNews https://t.co/lejtGs0hwu https://t.co/PmkZdO0xFj
-
-
Mashup Score: 9
Petros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Trials Needed for Sequencing Checkpoint Inhibitors in Bladder Cancer | #blcsm @PGrivasMDPhD @fredhutch https://t.co/aPtPQbUGH5
-
-
Mashup Score: 4
Phase 1 trial findings showed that GD2-CAR T-cell therapy induced significant tumor regressions and neurological improvements in patients with H3K27M-mutant diffuse midline gliomas.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
A phase 1 clinical trial investigating the use of GD2-targeted CAR T cells in H3K27M-mutant diffuse midline gliomas yielded promising results, demonstrating the feasibility, safety, and early efficacy of this approach. https://t.co/a7uDtw9rSP
-
-
Mashup Score: 3
Oleg Gligich, MD, discusses utilizing circulating tumor DNA to assess patients with lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Oleg Gligich, MD, discusses utilizing circulating tumor DNA to assess patients with lung cancer. #lcsm https://t.co/NlEr7hV84E
-
HBI-8000 + nivolumab showed promising efficacy and tolerability in patients with melanoma and no prior anti–PD-1/PD-L1 treatment, according to findings from a phase 2 trial. #SITC24 #melsm https://t.co/ReeuyCw1YE